期刊文献+

多发性骨髓瘤患者血清胱抑素C水平测定 被引量:6

Clinical Significance of Cystatin-C in Patients with Multiple Myeloma
原文传递
导出
摘要 目的测定多发性骨髓瘤(MM)患者血清胱抑素C(Cys-C)的水平,探讨Cys-C与国际分期体系(ISS)、血β2-微球蛋白、溶骨性损害等指标的关系。方法收集2008年1月-2010年9月32例初治和8例复发的MM患者作为研究对象,同时收集40例健康体检者的检查资料作为对照组,测定血清Cys-C、血肌酐(Scr)、血β2-微球蛋白。采用核素全身骨显像(ECT)观察患者的溶骨性病变部位数。结果患者血清Cys-C水平(1.40 mg/L)明显高于健康对照组(0.90 mg/L)(P<0.01);在MM患者中Cys-C比Scr更敏感,能反映肾小球滤过率;血清Cys-C水平与ISS分期晚,血β2-微球蛋白升高以及溶骨性病变进展密切相关。结论 MM患者的Cys-C水平高于健康者。Cys-C是骨髓瘤肾损害的早期敏感标志物,与肿瘤负荷及溶骨性损害密切相关,可作为评价肿瘤负荷的潜在指标。 Objective To evaluate the serum levels of cystatin-C in patients with multiple myeloma(MM),and to explore its possible correlations with clinical data,including ISS stage,serum β2-microglobulin,and advanced lytic lesions.Methods From January 2008 to September 2010,serum cystatin-C,creatinine(Scr),and β2-microglobulin in 32 patients with MM,8 patients with relapsed disease,and in 40 healthy controls were detected by automatic biochemistry analyzer detection.According to skeleton ECT,grading of osteolytic lesion was observed.Results The levels of serum cystatin-C of patients with MM were significantly higher than those of the controls.Serum cystatin-C could reflect the glomerular filtration rate,and was more sensitive than Scr in patients with renal lesion.Serum cystatin-C had stronger correlations with advanced ISS stages,high levels of serum β2-microglobulin,and extensive bone diseases.Conclusion Serum cystatin-C is a sensitive marker of renal lesion in patients with MM,it could be a potential indicator to assess the tumor burden.
作者 肖蓉
出处 《华西医学》 CAS 2012年第2期171-173,共3页 West China Medical Journal
关键词 多发性骨髓瘤 血清胱抑素C 肾功能损害 肿瘤负荷 溶骨性损害 Multiple myeloma Cystatin-C Renal impairment Tumor burden Lytic lesions
  • 相关文献

参考文献15

  • 1Abbott KC,Agodoal LY.Multiple myeloma and light chainassociated nephropathy at end-stage renal disease in the UnitedStates:patient characteristics and survival[J].Clin Nephrol,2001,56(3):207-210.
  • 2Lamb EJ,Stowe HJ,Simpson DE,et al.Diagnostic accuracy ofcystatin C as a marker of kidney disease in patients with multiplemyeloma:calculated glomerular filtration rate formulas are equallyuseful[J].Clin Chem,2004,50(10):1848-1851.
  • 3Heidtmann HH,Salge U,Abrahamson M,et al.Cathepsin B andcysteine proteinase inhibitors in human lung cancer cell lines[J].ClinExp Metastasis,1997,15(4):368-381.
  • 4Kos J,Stabuc B,Cimerman N,et al.Serum cystatin C,a newmarker of glomerular filtration rate,is increased during malignantprogression[J].Clin Chem,1998,44(11):2256-2257.
  • 5De Vos J,Thykjaer T,Tarte K,et al.Comparison of gene expressionprofiling between malignant and normal plasma cells witholigonucleotide arrays[J].Oncogene,2002,21(44):6848-6857.
  • 6Herget-Rosenthal S,Marggraf G,Hüsing J,et al.Early detection ofacute renal failure by serum cystatin C[J].Kidney Int,2004,66(3):1115-1122.
  • 7Perkins BA,Nelson RG,Ostrander BE,et al.Detection of renalfunction decline in patients with diabetes and normal or elevatedGFR by serial measurements of serum cystatin C concentration:esults of a 4-year follow-up study[J].J Am Soc Nephrol,2005,16(5):1404-1412.
  • 8Stevens LA,Coresh J,Schmid CH,et al.Estimating GFR usingserum cystatin C alone and in combination with serum creatinine:apooled analysis of 3,418 individuals with CKD[J].Am J Kidney Dis,2008,51(3):395-406.
  • 9Gertz MA,Lacy MQ,Dispenzieri A,et al.Impact of age and serumcreatinine value on outcome after autologous blood stem celltransplantation for patients with multiple myeloma[J].Bone MarrowTransplant,2007,39(10):605-611.
  • 10Eleutherakis-Papaiakovou V,Bamia A,Gika D,et al.Renal failurein multiple myeloma:incidence correlations,and prognosticsignificance[J].Leuk Lymphoma,2007,48(2):337-341.

同被引文献60

  • 1冯穗华,方群,陈健生,王昌云.胎儿血清β_2-微球蛋白及α_1-微球蛋白评估泌尿系畸形胎儿肾功能[J].中华小儿外科杂志,2005,26(9):467-471. 被引量:9
  • 2邱蔚六 主编.口腔颌面外科理论与实践[M].北京:人民卫生出版社,2004.521-522.
  • 3杨秀,王庆文,王金泉,陈惠萍,曾彩虹,刘志红,黎磊石,金洁.多发性骨髓瘤肾损害尿蛋白性质的分析及临床意义[J].医学研究生学报,2007,20(3):290-294. 被引量:8
  • 4Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma:presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern ivied, 1998; 158 ( 17 ) : 1889 - 1893.
  • 5Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated byrenal failure with bortezomib- based regimens. Leuk Lymphoma,2008 ;49 ( 5 ) : 890 - 895.
  • 6Wirk B. Renal failure in multiple myeloma: a medical emergency.Bone Marrow Transplant,2011 ;46 (6) :771 - 783.
  • 7Elie R. Dimethyl sulphoxide does not contribute to renal failure in patients undergoing stem cell Ixansplant for multiple myeloma and primary amyloidosis: Blood Thransfus,2012 ; 10 ( 1 ) : 104 - 105.
  • 8Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 2008 ; 22 ( 8 ) : 1485 - 1493.
  • 9Blumsohn A, Morris BW, Griffiths H, et al. Stability of beta 2- microglobulin and retinol binding protein at different values of PH and temperature in normal and pathological urine. Clin Chim Aeta, 1991 ;195(3) :133 -137.
  • 10Hong JD ,Lim IS. Correlation between glomerular filtration rate and urinary N acetyl-beta-D ghicosaminidase in children with persistent proteinuria in chronic glomerular disease. Korean J Pediatr,2012 ;55 (4) :136 - 142.

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部